All In MedTech

Device Trial Radar · NCT07633535

LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients

Association of LVAD Index With Selected Hepatic and Renal Biochemical Markers and Rehospitalization in HVAD and HeartMate 3 Continuous-Flow Left Ventricular Assist Devices

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Oct 1, 2022

Primary completion

Apr 30, 2023

Study completion Apr 30, 2023

Sponsor

Lead sponsor
Gaziantep City HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Antalya City Hospital; Akdeniz University Hospital
First posted
Jun 8, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-center, observational study evaluated the LVAD index, defined as device-estimated pump flow divided by body surface area, in adult patients supported with continuous-flow left ventricular assist devices. The study included 34 patients with end-stage heart failure who had either an HVAD or HeartMate 3 device and were followed for six months. The study assessed the relationship between LVAD index and selected routine biochemical markers related to hepatic and renal status, including ALT, AST, LDH, BUN, and creatinine. The study also evaluated whether LVAD index was associated with rehospitalization during follow-up.

Conditions

  • End-stage Heart Failure
  • Left Ventricular Assist Device
  • Mechanical Circulatory Support

Interventions

  • HeartWare Ventricular Assist DeviceDevice

    Patients in this group were supported with the HeartWare Ventricular Assist Device as part of routine clinical care. No device assignment or protocol-driven intervention was performed by the study investigators.

  • HeartMate 3 Left Ventricular Assist DeviceDevice

    Patients in this group were supported with the HeartMate 3 left ventricular assist device as part of routine clinical care. No device assignment or protocol-driven intervention was performed by the study investigators.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Association Between LVAD Index and Selected Biochemical MarkersTime frame: Six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Akdeniz University Faculty of Medicine

    Antalya, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.